Tirzepatide Reduces Body Weight by 21% in Adults with Obesity: SURMOUNT-1 Trial Results
Jastreboff AM, Aronne LJ, Ahmad NN, et al.
Summary
In a randomized controlled trial of 2,539 adults with obesity, tirzepatide at the highest dose (15mg) produced a mean weight reduction of 20.9% over 72 weeks, significantly outperforming placebo.
Clinical Significance
This landmark trial established tirzepatide as the most effective FDA-approved pharmacotherapy for obesity, with nearly 1 in 3 patients achieving ≥25% weight loss.
Primary Endpoint: Weight Loss at 72 Weeks
| Dose | Weight Loss | vs Placebo |
|---|---|---|
| Tirzepatide 5mg | −15.0% | p < 0.001 |
| Tirzepatide 10mg | −19.5% | p < 0.001 |
| Tirzepatide 15mg | −20.9% | p < 0.001 |
| Placebo | −3.1% | — |
Key stat: Nearly 1 in 3 patients on the highest dose lost ≥25% of body weight.
Secondary Endpoints
Waist circumference decreased by 14.4–19.9 cm with tirzepatide vs 4.0 cm with placebo.
Metabolic improvements:
- HbA1c reduction in pre-diabetic patients
- Improvements in lipid profiles (LDL, triglycerides)
- Blood pressure reductions across all dose groups
Safety Profile
- Most common AEs: Nausea, diarrhea, constipation (mild to moderate)
- Discontinuation rate: 4.3–7.1% due to GI adverse events
- CV safety: No significant cardiovascular safety signals
Clinical Implications
Tirzepatide's dual GIP/GLP-1 mechanism produces superior weight loss compared to GLP-1-only agents. The dual incretin approach appears to enhance appetite suppression and metabolic effects beyond what single-receptor agonists achieve.
Sources
相关研究
Gastrointestinal Adverse Events Associated with Tirzepatide: A Pharmacovigilance Analysis
A bibliometric and pharmacovigilance analysis of tirzepatide's gastrointestinal side effects, provid…
Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: SURPASS-CVOT
In a post hoc analysis of the landmark SURPASS-CVOT trial (n=13,165), tirzepatide demonstrated a 16%…
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: TOGETHER-PsA Trial
In the TOGETHER-PsA trial (n=271), combining tirzepatide with ixekizumab achieved ACR50 + ≥10% weigh…
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…